Medtronic PLC vs Unum Group Common Stock — how do they compare? Medtronic PLC trades at $94.74 (market cap $118.97B), while Unum Group Common Stock trades at $91.42 (market cap $14.57B). The key difference: Medtronic PLC is far larger — about 8.2× Unum Group Common Stock's market cap, and Medtronic PLC pays the higher dividend (3.1%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Unum Group Common Stock for 0 Days on average.
| MDT | UNM | |
|---|---|---|
Market Cap | $118.97B | $14.57B |
Volume | 24,932,018 | 1,461,588 |
Sector | Health | Financials |
52-Week High | $105.35 | $96.57 |
52-Week Low | $73.75 | $70.66 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $138.31B | $18.14B |
Dividend Yield | 3.1% | 2.19% |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $94.23, up 2.5% with strong technical momentum near resistance at $95. The stock shows solid fundamentals with consistent earnings beats, 13.93% net margins, and a 49-year dividend growth streak. Recent CPT code approvals for medical devices and raised 2026 guidance signal operational strength. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near-term.
MDT offers value with 3.2% dividend yield and 7%+ revenue growth, though debt levels have risen to 31.1% of assets. Analyst consensus remains strongly bullish (61% buy ratings) with $97.73 price target. Key risks include execution of the MiniMed separation and medical device competition. The stock presents a balanced opportunity for income and growth investors.
Unum Group (UNM) trades at $92.05, down 0.5% with neutral technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Analyst consensus is positive with 50% buy ratings and a $101 price target representing 9.7% upside. The company maintains stable profitability with 5.31% net margin and recently announced a $1 billion share repurchase program to enhance shareholder returns.
UNM presents a balanced investment case with strong institutional support and shareholder-friendly capital returns, though earnings consistency remains a concern. The stock trades at reasonable valuations (P/E 21.36, P/S 1.15) with potential upside to analyst targets. Key risks include premium growth sustainability and claims experience volatility in the insurance operations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Unum Group provides workplace benefits, including disability, life, accident, critical illness, dental, and vision insurance, along with leave management services. It serves employers through its Unum US, Unum International, and Colonial Life segments, distributing coverage via brokers and independent agents.
Read more on UNM →